Showing results (31-40 of 157) with videos related to

Sort By:
Pageof 16
Pharmacogenetics and Genomics|October 16, 2008
Effects of the SLCO1B1*1B haplotype on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinideAnnikka Kalliokoski, Janne T Backman, Pertti J Neuvonen, et al.
British Journal of Clinical Pharmacology|September 13, 2003
Effect of rifampicin on the pharmacokinetics and pharmacodynamics of nateglinide in healthy subjectsMikko Niemi, Janne T Backman, Mikko Neuvonen, et al.
European Journal of Clinical Pharmacology|March 3, 2007
Stereoselective interaction between the CYP2C8 inhibitor gemfibrozil and racemic ibuprofenAleksi Tornio, Mikko Niemi, Pertti J Neuvonen, et al.
Expert Opinion on Drug Metabolism & Toxicology|August 23, 2016
Role of gemfibrozil as an inhibitor of CYP2C8 and membrane transportersAleksi Tornio, Pertti J Neuvonen, Mikko Niemi, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|October 5, 2007
Trimethoprim and the CYP2C8*3 allele have opposite effects on the pharmacokinetics of pioglitazoneAleksi Tornio, Mikko Niemi, Pertti J Neuvonen, et al.
European Journal of Clinical Pharmacology|November 14, 2020
Incidence, preventability, and causality of adverse drug reactions at a university hospital emergency departmentMirjam Kauppila, Janne T Backman, Mikko Niemi, et al.
Trends in Pharmacological Sciences|April 6, 2012
Drug interactions with oral antidiabetic agents: pharmacokinetic mechanisms and clinical implicationsAleksi Tornio, Mikko Niemi, Pertti J Neuvonen, et al.
Clinical Pharmacology and Therapeutics|December 24, 2002
Gemfibrozil greatly increases plasma concentrations of cerivastatinJanne T Backman, Carl Kyrklund, Mikko Neuvonen, et al.
Clinical Pharmacology and Therapeutics|August 9, 2005
Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolitesJanne T Backman, Harri Luurila, Mikko Neuvonen, et al.
Basic & Clinical Pharmacology & Toxicology|September 10, 2011
Gender, but not CYP7A1 or SLCO1B1 polymorphism, affects the fasting plasma concentrations of bile acids in human beingsXiaoqiang Xiang, Janne T Backman, Pertti J Neuvonen, et al.
Pageof 16